Please ensure Javascript is enabled for purposes of website accessibility

GlaxoSmithKline Signs Potential $600 Million-Plus Cancer Immunotherapy Research-Partnership Deal

By Eric Volkman - Feb 20, 2020 at 6:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The global pharmaceutical giant will team up with a German biotech to research and develop T-cell based therapies.

GlaxoSmithKline (GSK 2.20%) is opening yet another new front in the war on cancer. The company is partnering with a privately held clinical-stage biotech based in Germany, Immatics Biotechnologies, to develop immunotherapies aimed at eradicating a range of cancer indications.

In this strategic-collaboration arrangement, Glaxo will make an upfront payment of $50 million to Immatics. In return, it will be granted access to two cancer immunotherapy research-and-development programs being run by the German company.

After that, Immatics stands to make at least $550 million more from the Glaxo cancer partnership if and when it meets certain development, regulatory, and commercial milestones. It will also be eligible for royalty payments. Finally, Glaxo has an option to choose new programs to include as part of the two companies' overall agreement.

Cancer immunotherapy.

Image source: Getty Images

Immatics' research concentrates on Adoptive Cell Therapy (ACT), a form of immunotherapy in which T-cells, either natural or engineered, are programmed and then introduced to a patient to attack his or her cancer.

In its press release announcing the Glaxo partnership, Immatics said that "[b]y combining Immatics' world-leading target and [T-cell receptor] discovery platforms with GSK's advanced manufacturing, development capabilities and a commitment to next-generation TCR-T technologies, both companies are joining forces to enable the development of effective novel therapies for cancer patients with high unmet medical need."

The partnership is the latest in a series of efforts made by Glaxo to boost its oncology profile. Over the past few years, its pipeline of drug candidates targeting cancer has widened significantly.

Glaxo, a top global pharmaceutical stock, closed down slightly in trading on Thursday.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.52 (2.20%) $0.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.